Changes Since 31 December 2013. Except as a result of the execution and delivery of this Agreement from 31 December 2013 to the date of this Agreement: 2.4.1 the Business has been conducted in all material respects in the ordinary and usual course; 2.4.2 no member of the Seller’s Group has entered into any material contract or commitment outside the ordinary course of business in respect of the Business as conducted prior to 31 December 2013; and 2.4.3 to the Seller’s knowledge, there has been no event or circumstance arising which is reasonably likely to have had a Material Adverse Effect (as if reference in the definition of “Material Adverse Effect” to the date of this Agreement were to 31 December 2013).
Appears in 3 contracts
Samples: Sale and Purchase Agreement (Glaxosmithkline PLC), Sale and Purchase Agreement (Novartis Ag), Sale and Purchase Agreement (Novartis Ag)
Changes Since 31 December 2013. Except as a result of the execution and delivery of this Agreement from 31 December 2013 to the date of this Agreement:
2.4.1 2.6.1 the Seller’s Contributed Business has been conducted in all material respects in the ordinary and usual course;
2.4.2 no member of 2.6.2 the Seller’s Group Contributed Business has not entered into any material contract or commitment outside the ordinary course of business in respect of the Business as conducted prior to 31 December 2013; and
2.4.3 2.6.3 to the Seller’s knowledge, there has been no event or circumstance arising which is reasonably likely to have had a Material Adverse Effect (as if reference in the definition of “Material Adverse Effect” Effect to the date of this Agreement were to 31 December 2013).
Appears in 3 contracts
Samples: Contribution Agreement (Glaxosmithkline PLC), Contribution Agreement (Glaxosmithkline PLC), Contribution Agreement (Novartis Ag)